JP4446601B2 - Ｂ群連鎖球菌の糖質を免疫学的に模倣する抗イディオタイプ抗体を含むワクチン処方物 - Google Patents

Ｂ群連鎖球菌の糖質を免疫学的に模倣する抗イディオタイプ抗体を含むワクチン処方物 Download PDF

Info

Publication number
JP4446601B2
JP4446601B2 JP2000544789A JP2000544789A JP4446601B2 JP 4446601 B2 JP4446601 B2 JP 4446601B2 JP 2000544789 A JP2000544789 A JP 2000544789A JP 2000544789 A JP2000544789 A JP 2000544789A JP 4446601 B2 JP4446601 B2 JP 4446601B2
Authority
JP
Japan
Prior art keywords
compound
protein
composition
streptococcus
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2000544789A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002512026A5 (https=
JP2002512026A (ja
Inventor
ジュゼッペ テチ，
ルチアーノ ポロネリ，
Original Assignee
カイロン ソチエタ ア レスポンサビリタ リミタータ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by カイロン ソチエタ ア レスポンサビリタ リミタータ filed Critical カイロン ソチエタ ア レスポンサビリタ リミタータ
Publication of JP2002512026A publication Critical patent/JP2002512026A/ja
Publication of JP2002512026A5 publication Critical patent/JP2002512026A5/ja
Application granted granted Critical
Publication of JP4446601B2 publication Critical patent/JP4446601B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4233—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-bacterial Ig
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2000544789A 1998-04-20 1999-04-20 Ｂ群連鎖球菌の糖質を免疫学的に模倣する抗イディオタイプ抗体を含むワクチン処方物 Expired - Fee Related JP4446601B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9808327.2 1998-04-20
GBGB9808327.2A GB9808327D0 (en) 1998-04-20 1998-04-20 Antidiotypic compounds
PCT/IB1999/000799 WO1999054457A1 (en) 1998-04-20 1999-04-20 Vaccine formulations comprising antiidiotypic antibodies which immunologically mimic group b streptococcal carbohydrates

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2009123637A Division JP2009179645A (ja) 1998-04-20 2009-05-21 Ｂ群連鎖球菌の糖質を免疫学的に模倣する抗イディオタイプ抗体を含むワクチン処方物

Publications (3)

Publication Number Publication Date
JP2002512026A JP2002512026A (ja) 2002-04-23
JP2002512026A5 JP2002512026A5 (https=) 2006-06-15
JP4446601B2 true JP4446601B2 (ja) 2010-04-07

Family

ID=10830608

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2000544789A Expired - Fee Related JP4446601B2 (ja) 1998-04-20 1999-04-20 Ｂ群連鎖球菌の糖質を免疫学的に模倣する抗イディオタイプ抗体を含むワクチン処方物
JP2009123637A Withdrawn JP2009179645A (ja) 1998-04-20 2009-05-21 Ｂ群連鎖球菌の糖質を免疫学的に模倣する抗イディオタイプ抗体を含むワクチン処方物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2009123637A Withdrawn JP2009179645A (ja) 1998-04-20 2009-05-21 Ｂ群連鎖球菌の糖質を免疫学的に模倣する抗イディオタイプ抗体を含むワクチン処方物

Country Status (9)

Country Link
US (2) US6676938B1 (https=)
EP (1) EP1071763B1 (https=)
JP (2) JP4446601B2 (https=)
AT (1) ATE425251T1 (https=)
CA (1) CA2325566C (https=)
CY (1) CY1109140T1 (https=)
DE (1) DE69940545D1 (https=)
GB (1) GB9808327D0 (https=)
WO (1) WO1999054457A1 (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6424300A (en) * 1999-05-27 2000-12-18 Max-Delbruck-Centrum Fur Molekulare Medizin Vaccines against conformation-dependent antigens and against antigens that are not or are not only proteins or peptides
DK1328543T3 (da) 2000-10-27 2009-11-23 Novartis Vaccines & Diagnostic Nukleinsyrer og proteiner fra streptococcus-gruppe A & B
AU2003260102A1 (en) * 2002-08-26 2004-03-11 Chiron Corporation Conserved and specific streptococcal genomes
JP4875490B2 (ja) 2003-07-31 2012-02-15 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド ＳｔｒｅｐｔｏｃｏｃｃｕｓＰｙｏｇｅｎｅｓについての免疫原組成物
US8945589B2 (en) 2003-09-15 2015-02-03 Novartis Vaccines And Diagnostics, Srl Immunogenic compositions for Streptococcus agalactiae
EP1784211A4 (en) * 2004-07-29 2010-06-30 Novartis Vaccines & Diagnostic IMMUNOGENIC COMPOSITIONS FOR GRAMPOSITIVE BACTERIA SUCH AS STREPTOCOCCUS AGALACTIAE
WO2006042027A2 (en) * 2004-10-08 2006-04-20 Novartis Vaccines And Diagnostics Inc. Immunogenic and therapeutic compositions for streptococcus pyogenes
EP1828231A2 (en) * 2004-12-22 2007-09-05 Novartis Vaccines and Diagnostics, Inc. Group b streptococcus
NZ599345A (en) 2005-02-18 2013-07-26 Novartis Vaccines & Diagnostic Immunogens from uropathogenic Escherichia Coli
DK2054431T3 (da) * 2006-06-09 2012-01-02 Novartis Ag Konformere af bakterielle adhæsiner
WO2008020330A2 (en) 2006-08-16 2008-02-21 Novartis Ag Immunogens from uropathogenic escherichia coli
WO2008108830A2 (en) * 2006-10-30 2008-09-12 Novartis Ag Immunogenic and therapeutic compositions for streptococcus pyogenes
CA2699513C (en) 2007-09-12 2018-03-13 Novartis Ag Gas57 mutant antigens and gas57 antibodies
PL2235046T3 (pl) * 2007-12-21 2012-12-31 Novartis Ag Zmutowane formy streptolizyny O
WO2012019168A2 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
RU2013120302A (ru) 2010-10-01 2014-11-20 Модерна Терапьютикс, Инк. Сконструированные нуклеиновые кислоты и способы их применения
EP2691101A2 (en) 2011-03-31 2014-02-05 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
RU2648950C2 (ru) 2011-10-03 2018-04-02 Модерна Терапьютикс, Инк. Модифицированные нуклеозиды, нуклеотиды и нуклеиновые кислоты и их применение
CN104114572A (zh) 2011-12-16 2014-10-22 现代治疗公司 经修饰的核苷、核苷酸和核酸组合物
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
AU2013243948A1 (en) 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins associated with human disease
WO2014081507A1 (en) 2012-11-26 2014-05-30 Moderna Therapeutics, Inc. Terminally modified rna
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
JP2016538829A (ja) 2013-10-03 2016-12-15 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 低密度リポタンパク質受容体をコードするポリヌクレオチド
WO2019199850A1 (en) 2018-04-10 2019-10-17 Gary A. Zwick, Trustee Of The Everest Trust Uta April 20, 2017 Spinal interbody cage comprising top and bottom faces with mesh structures, pillars and slots

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5476784A (en) * 1993-04-06 1995-12-19 Rice; Peter A. Gonococcal anti-idiotypic antibodies and methods and compositions using them
EP1015489B1 (en) * 1996-05-29 2006-07-05 Derek Nigel John Hart Dendritic cell receptor
US6140091A (en) * 1997-06-20 2000-10-31 Boston Biomedical Research Institute Anti-idiotype vaccines to elicit catalytic antibodies
US6444787B1 (en) * 1997-12-31 2002-09-03 Research Development Institute, Inc. Method of isolating a peptide which immunologically mimics microbial carbohydrates including group B streptococcal carbohydrates and the use thereof in a vaccine

Also Published As

Publication number Publication date
EP1071763A1 (en) 2001-01-31
US6900302B2 (en) 2005-05-31
GB9808327D0 (en) 1998-06-17
CA2325566C (en) 2011-02-08
ATE425251T1 (de) 2009-03-15
DE69940545D1 (de) 2009-04-23
JP2002512026A (ja) 2002-04-23
WO1999054457A1 (en) 1999-10-28
EP1071763B1 (en) 2009-03-11
US20040101536A1 (en) 2004-05-27
CY1109140T1 (el) 2014-07-02
CA2325566A1 (en) 1999-10-28
US6676938B1 (en) 2004-01-13
JP2009179645A (ja) 2009-08-13

Similar Documents

Publication Publication Date Title
JP4446601B2 (ja) Ｂ群連鎖球菌の糖質を免疫学的に模倣する抗イディオタイプ抗体を含むワクチン処方物
JP4012687B2 (ja) ポリエピトープキャリアタンパク質
JP4840745B2 (ja) 熱ショックタンパク質とオリゴ糖または多糖とから形成されるコンジュゲート
AU2016207099C1 (en) Virus-like particle with efficient epitope display
JP5931724B2 (ja) ＳｔｒｅｐｔｏｃｏｃｃｕｓＰｎｅｕｍｏｎｉａｅに対するワクチンおよび組成物
JPH08508252A (ja) 小胞体シグナル配列ペプチドと少なくとも１個の他のペプチドをエンコードする核酸配列を含有する免疫原性キメラ、及びこのキメラのワクチン及び疾患の治療における使用
JPH07507688A (ja) ジフテリア毒素ワクチン
MXPA01005389A (es) Presentacion molecular ordenada de antigenos, metodos de preparacion y uso.
JP2009515831A (ja) ペスト菌（Ｙｅｒｓｉｎｉａｐｅｓｔｉｓ）抗原を含む組成物
US6737521B1 (en) Delivery and expression of a hybrid surface protein on the surface of gram positive bacteria
JP2015534822A (ja) 条件的弱毒化細菌種ならびにその調製法および使用法
AU642650B2 (en) Compositions and treatments for pneumonia in animals
JP4653934B2 (ja) バクテリオファージによって仲介される免疫化方法
US12383630B2 (en) Immunogenic peptide against group a Streptococcus
AU3919993A (en) Delivery and expression of a hybrid surface protein on the surface of gram positive bacteria
JP2002514061A (ja) 肺炎球菌ｄｎａを投与するための組成物および方法
TW201809274A (zh) 蛋白質表現強化子序列及其用途
MXPA02006313A (es) Vacunacion de acido nucleico.
JP4535874B2 (ja) 肝炎に対するバクテリオファージを介する免疫
US6534067B1 (en) Rotavirus enterotoxin adjuvant
JP2024526293A (ja) 淋菌を標的とするワクチン
JPH07507447A (ja) 異種の免疫刺激ドメインをその配列内に含む組換え抗原−ワクチンとしてのその使用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060406

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060406

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090323

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090521

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090825

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091029

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20091221

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20100119

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130129

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130129

Year of fee payment: 3

LAPS Cancellation because of no payment of annual fees